A novel mutation in TAZ causes mitochondrial respiratory chain disorder without cardiomyopathy

Tafazzin, encoded by the taz gene, is a mitochondrial membrane-associated protein that remodels cardiolipin (cl), an important mitochondrial phospholipid. taz mutations are associated with barth syndrome (bths). bths is an x-linked multisystemic disorder affecting usually male patients. through sequence analysis of taz, we found one novel mutation c.39_60del p.(pro14alafs*19) by whole-exome sequencing and a reported missense mutation c.280c>t p.(arg94cys) by sanger sequencing in two male patients (pt1 and pt2). patient with c.280c>t mutation had dilated cardiomyopathy, while another patient with c.39_60del mutation had no feature of cardiomyopathy. a reported m.1555a>g homoplasmic variant was also identified in the patient having mutation c.39_60del by whole mitochondrial dna sequencing method. this variant was not considered to be the main cause of mitochondrial dysfunction based on a cytoplasmic hybrid (cybrid) assay. tafazzin expression was absent in both patient-derived fibroblast cells. complementation of taz expression in fibroblasts from the patient with the novel mutation c.39_60del restored mitochondrial respiratory complex assembly. high-performance liquid chromatography–tandem mass spectrometry-based metabolic analysis revealed the decline of cl and the accumulation of monolysocardiolipin, indicating the loss of tafazzin activity. owing to phenotypic variability, it is difficult to diagnose bths based on clinical features only. we conclude that genetic analysis should be performed to avoid underdiagnosis of this potentially life-threatening inborn error of metabolism.